Neuphoria Therapeutics (NEUP) Other Non Operating Income (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Other Non Operating Income of -$291522.0 for Q1 2026, down 268.56% year-over-year from $172946.0 in Q1 2025, and down 105.42% on a QoQ basis from $5.4 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Other Non Operating Income data on file, last reported at -$291522.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 268.56% year-over-year to -$291522.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 69.27% YoY) and the FY2025 annual result came in at -$414996.0, down 118.8% from the prior year.
- Other Non Operating Income retreated to -$291522.0 in Q1 2026 per NEUP's latest filing, from $5.4 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $5.4 million in Q4 2025 and bottomed at -$3.1 million in Q2 2025.
- The 4-year median for Other Non Operating Income is $172946.0 (2025), against an average of $724390.1.
- The widest annual swing landed in 2024, when Other Non Operating Income surged 175922.26%; it then tumbled 268.56% in 2026.
- Tracing NEUP's Other Non Operating Income over 4 years: stood at -$363508.0 in 2023, then jumped by 321.57% to $805422.0 in 2024, then soared by 567.91% to $5.4 million in 2025, then slumped by 105.42% to -$291522.0 in 2026.
- Per Business Quant, the three latest NEUP Other Non Operating Income figures stand at -$291522.0 (Q1 2026), $5.4 million (Q4 2025), and -$61735.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -291,522.00 |
| Dec 31, 2025 | -135,659.00 |
| Sep 30, 2025 | -61,735.00 |
| Jun 30, 2025 | -937,406.00 |
| Mar 31, 2025 | 172,946.00 |
| Dec 31, 2024 | 629,501.00 |
| Sep 30, 2024 | -280,037.00 |
| Jun 30, 2024 | 2.36 Mn |
| Mar 31, 2024 | 216,847.00 |
| Dec 31, 2023 | 177,726.00 |
| Sep 30, 2023 | -124,558.00 |